Abstract
Chuvash polycythemia is an autosomal recessive disorder that is endemic to the mid-Volga River region. We previously mapped the locus associated with Chuvash polycythemia to chromosome 3p25. The gene associated with von Hippel–Lindau syndrome, VHL, maps to this region, and homozygosity with respect to a C→T missense mutation in VHL, causing an arginine-to-tryptophan change at amino-acid residue 200 (Arg200Trp), was identified in all individuals affected with Chuvash polycythemia. The protein VHL modulates the ubiquitination and subsequent destruction of hypoxia-inducible factor 1, subunit α (HIF1α). Our data indicate that the Arg200Trp substitution impairs the interaction of VHL with HIF1α, reducing the rate of degradation of HIF1α and resulting in increased expression of downstream target genes including EPO (encoding erythropoietin), SLC2A1 (also known as GLUT1, encoding solute carrier family 2 (facilitated glucose transporter), member 1), TF (encoding transferrin), TFRC (encoding transferrin receptor (p90, CD71)) and VEGF (encoding vascular endothelial growth factor).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Prchal, J.T. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin. Hematol. 38, 10–20 (2001).
Jacobson, L.O., Goldwasser, E., Fried, W. & Plzak, L. Role of the kidney in erythropoiesis. 1957. J Am. Soc. Nephrol. 11, 589–590 (2000).
Shih, L.Y., Huang, J.Y. & Lee, C.T. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J. Am. Soc. Nephrol. 10, 315–322 (1999).
Sergeyeva, A. et al. Congenital polycythemia in Chuvashia. Blood 89, 2148–2154 (1997).
Polyakova, L.A. Familial-Hereditary Erythrocytosis (Scientific Research Institute of Hematology and Blood, Moscow, 1977).
Ang, S.O. et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol. Dis. 28, 57–62 (2002).
Maxwell, P.H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
Ivan, M. et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001).
Jaakkola, P. et al. Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 449–451 (2001).
Epstein, A.C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43–54 (2001).
Knudson, A.G. Antioncogenes and human cancer. Proc. Natl Acad. Sci. USA 90, 10914–10921 (1993).
Vasserman, N.N. et al. Localization of the gene responsible for familial benign polycythemia to chromosome 11q23. Hum. Hered. 49, 129–132 (1999).
Masson, N., William, C., Maxwell, P.H., Pugh, C.W. & Ratcliffe, P.J. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J. 20, 5197–5206 (2001).
Karasawa, Y. et al. Duodenal somatostatinoma and erythrocytosis in a patient with von Hippel–Lindau disease type 2A. Intern. Med. 40, 38–43 (2001).
Ohh, M. et al. The von Hippel–Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959–968 (1998).
Gordeuk, V.R. et al. High mortality due to thrombosis and cerebral hemorrhage in Chuvash polycythemia. Blood 98, 224a (2001).
Beroud, C. et al. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 26, 256–258 (1998).
Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein. Nature Cell Biol. 2, 423–427 (2000).
Hon, W.-C. et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975–978 (2002).
Min, J.-H. et al. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886–1889 (2002).
Clifford, S.C. et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel–Lindau disease. Hum. Mol. Genet. 10, 1029–1038 (2001).
Haase, V.H., Glickman, J.N., Socolovsky, M. & Jaenisch, R. Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor. Proc. Natl Acad. Sci. USA 98, 1583–1588 (2001).
Prchal, J.F. & Prchal, J.T. Molecular basis for polycythemia. Curr. Opin. Hematol. 6, 100–109 (1999).
Kralovics, R. & Prchal, J.T. Congenital and inherited polycythemia. Curr. Opin. Pediatr. 12, 29–34 (2000).
Stopka, T., Zivny, J.H., Stopkova, P., Prchal, J.F. & Prchal, J.T. Human hematopoietic progenitors express erythropoietin. Blood 91, 3766–3772 (1998).
Schaffer, A.A., Gupta, S.K., Shriram, K. & Cottingham, R.W. Jr., Avoiding recomputation in linkage analysis. Hum. Hered. 44, 225–237 (1994).
Jenkins, M.M. & Prchal, J.T. A novel mutation found in the 3′ domain of NADH-cytochrome B5 reductase in an African-American family with type I congenital methemoglobinemia. Blood 87, 2993–2999 (1996).
Mahon, P.C., Hirota, K. & Semenza, G.L. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675–2686 (2001).
Semenza, G.L. et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529–32537 (1996).
Jiang, B.H., Zheng, J.Z., Leung, S.W., Roe, R. & Semenza, G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272, 19253–19260 (1997).
Zhong, H. et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59, 5830–5835 (1999).
Zhong, H. & Simons, J.W. Direct comparison of GAPDH, β-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem. Biophy. Res. Commun. 259, 523–526 (1999).
Hagesawa, K., Anraku, Y., Kasahara, M., Akamatsu, Y. & Nishijima, M. Isolation and characterization of Chinese hamster ovary cell mutants defective in glucose transport. Biochim. Biophys. Acta 1051, 221–229 (1990).
Beutler, E. Red Cell Metabolism. A Manual of Biochemical Methods (Grune & Stratton, New York and London, 1971).
Acknowledgements
This work was supported by grants from the National Heart, Lung and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health. The authors would like to thank W. Kaelin for providing 786-O cells.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Ang, S., Chen, H., Hirota, K. et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32, 614–621 (2002). https://doi.org/10.1038/ng1019
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng1019
This article is cited by
-
Gene expression changes in sickle cell reticulocytes and their clinical associations
Scientific Reports (2023)
-
The effect of HIF on metabolism and immunity
Nature Reviews Nephrology (2022)
-
Abnormal whole-body energy metabolism in iron-deficient humans despite preserved skeletal muscle oxidative phosphorylation
Scientific Reports (2022)
-
PHD2 attenuates high-glucose-induced blood retinal barrier breakdown in human retinal microvascular endothelial cells by regulating the Hif-1α/VEGF pathway
Inflammation Research (2022)
-
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
Genome Medicine (2022)